• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Myomo Inc.

    5/28/26 4:23:53 PM ET
    $MYO
    Industrial Specialties
    Health Care
    Get the next $MYO alert in real time by email
    SD 1 copy_of_form_sd_-_2025.htm SD SD

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM SD

    SPECIALIZED DISCLOSURE REPORT

    Myomo, Inc.

    (Exact name of the registrant as specified in its charter)

    Delaware

    001-38109

    47-0944526

    (State or other jurisdiction of

    incorporation)

    (Commission

    File Number)

    (IRS Employer

    Identification No.)

    45 Blue Sky Dr., Suite 101,

    Burlington, Massachusetts

    01803

    (Address of principal executive offices)

    (Zip code)

    (617) 996-9058

    (Name and telephone number, including area code, of the person to contact in connection with this report.)

    Check the appropriate box to indicate the rule pursuant to which this form is being filed and provide the period to which the information in this form applies:

    ☑

    Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2025.

    ☐

    Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended ________.

     


    Section 1 - Conflict Minerals Disclosures

    Item 1.01 – Conflict Minerals Disclosure and Report

    A copy of the Company’s Conflict Minerals Report is provided as Exhibit 1.01 hereto and is publicly available at https://ir.myomo.com/corporate-governance/governance-documents

    Item 1.02 Exhibit

    Exhibit 1.01 – Conflict Minerals Report is attached per Section 1

    Section 2 – Resource Extraction Issuer Disclosure

    Item 2.01 Resource Extraction Issuer Disclosure and Report

    Not applicable.

    Section 3 - Exhibits

    Item 3.01 – Exhibits

    Exhibit 1.01 — Conflict Minerals Report of Myomo, Inc. for the year ended December 31, 2025, as required by Items 1.01 and 1.02 of this Form SD.

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

    MYOMO, INC.

    Date: May 28, 2026

    /s/ David Henry

    Name: David Henry

    Title: Chief Financial Officer

     

     

     

     

     


    Get the next $MYO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MYO

    DatePrice TargetRatingAnalyst
    7/31/2024$7.00Buy
    Craig Hallum
    5/20/2024$7.00Buy
    Lake Street
    12/15/2023$6.50Buy
    H.C. Wainwright
    More analyst ratings

    $MYO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kirk Thomas F bought $24,825 worth of shares (25,000 units at $0.99), increasing direct ownership by 4% to 653,863 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    6/1/26 8:23:56 AM ET
    $MYO
    Industrial Specialties
    Health Care

    Director Kirk Thomas F bought $68,243 worth of shares (75,006 units at $0.91), increasing direct ownership by 14% to 628,863 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    5/18/26 8:20:32 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Director Manko Joseph M. Jr. bought $173,908 worth of MYO (201,197 units at $0.86) (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    5/18/26 4:59:21 PM ET
    $MYO
    Industrial Specialties
    Health Care

    $MYO
    SEC Filings

    View All

    SEC Form SD filed by Myomo Inc.

    SD - MYOMO, INC. (0001369290) (Filer)

    5/28/26 4:23:53 PM ET
    $MYO
    Industrial Specialties
    Health Care

    SEC Form DEFA14A filed by Myomo Inc.

    DEFA14A - MYOMO, INC. (0001369290) (Filer)

    5/14/26 4:10:02 PM ET
    $MYO
    Industrial Specialties
    Health Care

    SEC Form DEF 14A filed by Myomo Inc.

    DEF 14A - MYOMO, INC. (0001369290) (Filer)

    5/14/26 4:05:31 PM ET
    $MYO
    Industrial Specialties
    Health Care

    $MYO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kirk Thomas F bought $24,825 worth of shares (25,000 units at $0.99), increasing direct ownership by 4% to 653,863 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    6/1/26 8:23:56 AM ET
    $MYO
    Industrial Specialties
    Health Care

    Chief Medical Officer Kovelman Harry sold $32,239 worth of shares (32,000 units at $1.01), decreasing direct ownership by 23% to 108,618 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    5/28/26 9:53:08 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Director Kirk Thomas F bought $68,243 worth of shares (75,006 units at $0.91), increasing direct ownership by 14% to 628,863 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    5/18/26 8:20:32 PM ET
    $MYO
    Industrial Specialties
    Health Care

    $MYO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on Myomo with a new price target

    Craig Hallum initiated coverage of Myomo with a rating of Buy and set a new price target of $7.00

    7/31/24 7:20:07 AM ET
    $MYO
    Industrial Specialties
    Health Care

    Lake Street initiated coverage on Myomo with a new price target

    Lake Street initiated coverage of Myomo with a rating of Buy and set a new price target of $7.00

    5/20/24 9:00:38 AM ET
    $MYO
    Industrial Specialties
    Health Care

    H.C. Wainwright initiated coverage on Myomo with a new price target

    H.C. Wainwright initiated coverage of Myomo with a rating of Buy and set a new price target of $6.50

    12/15/23 8:26:14 AM ET
    $MYO
    Industrial Specialties
    Health Care

    $MYO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Myomo Announces Participation in Upcoming Investor Conferences

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced its participation in two upcoming investor conferences. On May 20, Myomo's President and Chief Executive Officer Paul Gudonis and Chief Financial Officer David Henry will participate virtually in a fireside chat as part of Alliance Global Partners Annual Healthcare Company Showcase. The fireside chat will begin at 11:20 a.m ET. The registration link for the conference can be found here. Chief Financial Officer David Henry will present at Sidoti's Virtual Micro Cap Conference

    5/14/26 4:05:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Myomo Appoints Joseph M. Manko to its Board of Directors

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Joseph M. ("Joe") Manko Jr. as a director effective May 9, 2026, to serve until the 2027 annual meeting of stockholders. With this appointment, Myomo has seven directors. Mr. Manko is an accomplished investor with over 25 years of experience in investment banking, private equity, asset management and corporate strategy. Mr. Manko is currently the Senior Principal of Horton Capital Management LLC ("The Horton Fund"), a significant shareholder in the Company. Mr.

    5/13/26 4:05:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Myomo Reports First Quarter 2026 Financial and Operating Results

    Revenue of $10.1 million with 49% of first quarter revenue from recurring patient sources MyoPro® orders received during the quarter were up 12% year-over-year Expanded gross margin, lower operating expenses and narrowed net loss Conference call begins at 4:30pm Eastern time today Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months ended March 31, 2026. "Earlier this year we established four success pillars for 2026, including growing revenue from recurring patient sources, increasing

    5/7/26 4:05:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    $MYO
    Leadership Updates

    Live Leadership Updates

    View All

    Myomo Appoints Joseph M. Manko to its Board of Directors

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Joseph M. ("Joe") Manko Jr. as a director effective May 9, 2026, to serve until the 2027 annual meeting of stockholders. With this appointment, Myomo has seven directors. Mr. Manko is an accomplished investor with over 25 years of experience in investment banking, private equity, asset management and corporate strategy. Mr. Manko is currently the Senior Principal of Horton Capital Management LLC ("The Horton Fund"), a significant shareholder in the Company. Mr.

    5/13/26 4:05:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Myomo Appoints William J Febbo to its Board of Directors

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of William "Will" Febbo as a director effective April 14, 2026, to serve until the 2028 annual meeting of stockholders. With this appointment, Myomo has six directors. Mr. Febbo is an accomplished executive, entrepreneur, and investor with over 30 years of experience in healthcare, financial services, and technology-driven businesses. He has successfully guided organizations through substantial growth, strategic transformations and acquisitions, and significant ca

    4/16/26 4:05:00 PM ET
    $MYO
    $OPRX
    Industrial Specialties
    Health Care
    Real Estate

    Inogen Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West

    Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Mira Kirti Sahney to Inogen's Board of Directors, effective January 31, 2025. The company also announced that Tom West, who has served as a director since April 2023, retired as a member of the Board of Directors, effective January 30, 2025. "We are thrilled to welcome Mira Sahney to the Inogen Board. Mira brings considerable management, technical, and operational experience in the medical device field to Inogen," said Elizabeth Mora, Chairperson of the Board. "Mira's appointment will further strengthen Inogen's Board with a

    2/3/25 4:00:00 PM ET
    $INGN
    $MDT
    $MYO
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    $MYO
    Financials

    Live finance-specific insights

    View All

    Myomo Reports First Quarter 2026 Financial and Operating Results

    Revenue of $10.1 million with 49% of first quarter revenue from recurring patient sources MyoPro® orders received during the quarter were up 12% year-over-year Expanded gross margin, lower operating expenses and narrowed net loss Conference call begins at 4:30pm Eastern time today Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months ended March 31, 2026. "Earlier this year we established four success pillars for 2026, including growing revenue from recurring patient sources, increasing

    5/7/26 4:05:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Myomo to Report First Quarter 2026 Financial Results on May 7

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the first quarter ended March 31, 2026 on Thursday, May 7, 2026. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a dial-in number and PIN to bypass the live operator. Participants may pre-register at any time, including up to and after the call star

    5/1/26 4:05:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Myomo Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

    Fourth quarter revenue of $11.4 million, full year revenue of $40.9 million 42% of fourth quarter revenue from recurring patient sources Record 241 authorizations and orders in the quarter Introduces 2026 revenue guidance of $43 million to $46 million as Company emphasizes recurring sources of revenue Conference call begins today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months and year ended December 31, 2025. "We delivered 2025 revenue at the midpoint of o

    3/9/26 4:06:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    $MYO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Myomo Inc.

    SC 13G/A - MYOMO, INC. (0001369290) (Subject)

    10/18/24 2:21:35 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by Myomo Inc.

    SC 13G/A - MYOMO, INC. (0001369290) (Subject)

    7/12/24 10:35:49 AM ET
    $MYO
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by Myomo Inc.

    SC 13G/A - MYOMO, INC. (0001369290) (Subject)

    7/11/24 6:02:07 PM ET
    $MYO
    Industrial Specialties
    Health Care